80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]趙 珅 范南峰 李 惠 劉 捷 俞嘉青 林榕波.阿帕替尼聯(lián)合紫杉醇化療方案治療紫杉醇耐藥的晚期胃癌的臨床研究[J].福建醫(yī)藥雜志,2020,42(01):16-19.
　ZHAO Shen,FAN Nanfeng,LI Hui,et al.Clinical study of apatinib combined with paclitaxel chemotherapy in the treatment of paclitaxel-resistant advanced gastric cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(01):16-19.
點擊復(fù)制

阿帕替尼聯(lián)合紫杉醇化療方案治療紫杉醇耐藥的晚期胃癌的臨床研究()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期數(shù):
2020年01期
頁碼:
16-19
欄目:
臨床研究
出版日期:
2020-03-30

文章信息/Info

Title:
Clinical study of apatinib combined with paclitaxel chemotherapy in the treatment of paclitaxel-resistant advanced gastric cancer
文章編號:
1002-2600(2020)01-0016-04
作者:
趙 珅 范南峰 李 惠 劉 捷 俞嘉青 林榕波1
福建省腫瘤醫(yī)院 福建醫(yī)科大學(xué)附屬腫瘤醫(yī)院腹部腫瘤科(福州 350014)
Author(s):
ZHAO Shen;  FAN Nanfeng;  LI Hui;  LIU Jie;  YU Jiaqing;  LIN Rongbo.
Department of Abdominal Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian 350014,China
關(guān)鍵詞:
胃癌;  阿帕替尼;  耐藥性逆轉(zhuǎn);  含紫杉醇化療
Keywords:
gastric cancer;  apatinib;  reversal of multidrug resistance;  paclitaxel-contained regimens
分類號:
R735.2
文獻標(biāo)志碼:
A
摘要:
目的 評價阿帕替尼聯(lián)合紫杉醇化療方案在紫杉醇耐藥的晚期胃癌患者中的療效及安全性。方法 選取7例紫杉醇耐藥的晚期胃癌患者進行回顧性研究,其中4例給予850 mg阿帕替尼靶向治療同時聯(lián)合單藥紫杉醇化療,3例給予850 mg阿帕替尼靶向治療聯(lián)合紫杉醇+奧沙利鉑+氟尿嘧啶(POF)方案全身化療。結(jié)果 在到達(dá)研究截止時間時,6位患者死亡,中位無進展生存期(PFS)4.4個月[95%可信區(qū)間:(2.1,6.7)個月]; 中位總生存期(OS)6.9個月[95%可信區(qū)間:(1.8,12.0)個月]。7例患者中,6例行腫瘤反應(yīng)的評估,其中2例患者部分緩解(PR),4例患者疾病穩(wěn)定(SD),客觀反應(yīng)率28.6%[95%可信區(qū)間:(8.2%,64.1%)],疾病控制率87.5%[95%可信區(qū)間:(48.7%,97.4%)]。大多數(shù)的不良反應(yīng)輕或可控制。結(jié)論 對于紫杉醇耐藥的晚期胃癌患者,阿帕替尼聯(lián)合含紫杉醇的化療方案,可延長患者PFS并獲得較好的OS,不良反應(yīng)均為可耐受的。因此,這一方案有望成為紫杉醇耐藥晚期胃癌患者的治療選擇。
Abstract:
Objective The present study aimed to investigate the efficacy and safety of apatinib combined with paclitaxel-contained regimens in patients with advanced gastric cancer who experienced paclitaxel-contained treatment failure.Methods We retrospectively reviewed the medical records of seven patients with heavily pretreated advanced gastric cancer.These patients had progressive disease after prior treatment including paclitaxel-contained treatment.Apatinib was given to patients in combination with POF regimens or paclitaxel alone.Four of seven patients were treated with apatinib daily at initial dose of 850 mg combined with paclitaxel alone and three patients received apatinib combined with POF.Results At the time of data cutoff, six patients died, with median progression-free survival(PFS)of 4.4 months [95CI%:(2.1,6.7)months], and median overall survival(OS)of 6.9 months [95CI%:(1.8,12.0)months].Six of seven patients were evaluable for tumor response evaluation: two patients achieved partial remission(PR)and four patients achieved stable disease(SD), with an objective response rate of 28.6%[95%CI:(8.2%,64.1%)] and a disease control rate of 87.5%[95%CI:(48.7%,97.4%)].Most adverse events were mild and manageable.Conclusion The combination therapy of apatinib with paclitaxel-contained therapy could be a treatment option for patients with advanced or metastatic gastric cancer who experience paclitaxel-based treatment failure, with acceptable toxicity.

參考文獻/References:

[1] Torre L A, Bray F, Siegel R L, et al.Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[2] Van Cutsem E, Haller D, Ohtsu A.The role of chemotherapy in the current treatment of gastric cancer [J]. Gastric Cancer, 2002,5(Suppl 1):17-22.
[3] Lin R, Fan N, Wu G, et al.A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer [J]. J Chemother, 2015, 27(1): 52-56.
[4] Vasan N,Baselga J, Hyman D M.A view on drug resistance in cancer[J]. Nature,2019,575(7782): 299-309.
[5] Kathawala R J, Gupta P, Ashby C R Jr, et al.The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade [J]. Drug Resist Updat, 2015,18:1-17.
[6] Chen Y,Scully M,Petralia G,et al.Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells[J]. Cancer biology & therapy, 2014, 15(1):135-145.
[7] Wang J Q,Wang B,Lei Z N, et al.Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance[J].Eur J Pharmacol,2019,863,172611.
[8] Li J, Zhao X, Chen L, et al.Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies [J]. BMC Cancer, 2010,10:529.
[9] Tong X Z, Wang F, Liang S, et al.Apatinib(YN968D1)enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-over expressing leukemia cells [J]. Biochemical pharmacology,2012, 83(5): 586-597.
[10] Li J, Qin S, Xu J, et al.Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction[J]. J Clin Oncol, 2016, 34(13): 1448-1454.
[11] Mi Y J, Liang Y J, Huang H B, et al.Apatinib(YN968D1)reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters [J]. Cancer Res, 2010, 70(20): 7981-7991.
[12] Li J, Qin S, Xu J, et al.Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal Junction[J]. J Clin Oncol,2016, 34(13): 1448-1454.
[13] Zhu J, Li X,Xie C H, et al.Apatinib, a New Small Molecular VEGFR2 inhibitor, suppresses the activity of lung cancer stem cells[J]. J Thorac Oncol,2017, 12(suppl 1): s1279.
[14] Yu M, Gao Z, Dai X, et al.Population pharmacokinetic and covariate analysis of apatinib, an oral tyrosine kinase inhibitor, in healthy volunteers and patients with solid tumors[J]. Clin Pharmacokinet, 2017, 56(1): 65-76.

相似文獻/References:

[1]楊蔡江.胃癌癌組織中p27與cyclinD1的表達(dá)及臨床意義[J].福建醫(yī)藥雜志,2017,39(5):50.
[2]陳國平 陳劍明.多項腫瘤標(biāo)記物在胃癌診斷中的篩選及應(yīng)用價值[J].福建醫(yī)藥雜志,2019,41(02):4.
　CHEN Guoping,CHEN Jianming..Value of screening and application of multiple combined tumor markers in the diagnosis of gastric cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(01):4.
[3]呂美玲,賴麗萍,呂冬梅,等.干擾MS4A8對苦參堿抑制胃癌細(xì)胞生長的影響[J].福建醫(yī)藥雜志,2023,45(05):98.
[4]沈惠群,沈松菲.5-Aza-CdR對胃癌中SOX17基因表達(dá)的影響[J].福建醫(yī)藥雜志,2024,46(01):24.[doi:10.20148/j.fmj.2024.01.007]
[5]余煒,黃靜,余輝,等.基于介孔二氧化硅和聚多巴胺納米載體遞送阿帕替尼的性質(zhì)研究[J].福建醫(yī)藥雜志,2024,46(02):114.[doi:10.20148/j.fmj.2024.02.031]
　YU Wei,HUANG Jing,YU Hui,et al.Study on the properties of apatinib delivery based on mesoporous silica and polydopamine nanocarriers[J].FUJIAN MEDICAL JOURNAL,2024,46(01):114.[doi:10.20148/j.fmj.2024.02.031]

備注/Memo

備注/Memo:
基金項目:福建省醫(yī)學(xué)創(chuàng)新課題(2016-CX-12)1 通信作者,Email:[email protected]
更新日期/Last Update: 2020-03-30